Advanced BioScience Laboratories will participate in an Engility-led consortium that holds a prime position under a potential 10-year, $900 million contract awarded in January to help research and develop medical products for the U.S. Army.
ABL will collaborate with Engility to support the Army’s Medical Research and Materiel Command and aims to leverage its product development, manufacturing, testing and project management experience in the program, ABL said Thursday.
“We look forward to contributing to the advancement of critical medical research and products required by the Army and other Department of Defense entities,” noted Thomas VanCott, ABL president and CEO.
Rockville, Maryland-based ABL works with biopharmaceutical companies as well as government and academic organizations to help them produce therapeutic vaccines and biologic drugs.